choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Adcirca

Adcirca Newsletter
  • On the heels of pulmonary arterial hypertension drug nod, Merck launches 'Outnumber PAH' campaign 16 Apr 2024 15:19 GMT

    … after earning the FDA’s signoff on new drug Winrevair to … patients talk to their doctors about their care and … Winrevair—nor any other specific treatments for PAH. Winrevair’s … Opsumit, and United Therapeutics’ Adcirca, are focused on alleviating symptoms …

  • FDA Updates for Week of March 25: Two Approvals for PAH 30 Mar 2024 16:26 GMT

    … England Journal of Medicine in April 2023. In the trial, 38.9% … Cialis for erectile dysfunctin and Adcirca for PAH by Lilly. In … to $24,800 per treatment cycle. FDA Issues CRL for Odronextamab for … the confirmatory portions of these trials should be under way …

  • FDA Approves Combination Therapy for Pulmonary Arterial Hypertension 26 Mar 2024 15:32 GMT

    … for erectile dysfunctin and Adcirca for PAH by Lilly. … Hypertension Program at UT Southwestern Medical Center, and an investigator … had submitted the new drug application for the macitentan … three-arm trial enrolled patients who were treatment-naïve or on …

  • Merck scores key FDA approval for pulmonary arterial hypertension drug Winrevair 26 Mar 2024 23:55 GMT

    … launch the first disease-modifying treatment for the condition. Initially … the significant innovation this medicine can deliver as a … Opsumit an United Therapeutics’ Adcirca (tadalafil), which are often … investigation in late-stage trials for PH due to …

  • Bank on the Future Returns With These 3 Biotech Stocks 01 Mar 2024 16:50 GMT

    medicine. The pharma sector also uses biotechnology to accelerate drug … II trial of alisertib monotherapy for the treatment of … the U.S. FDA granted Orphan Drug Designation to alisertib … (treprostinil) injection, Orenitram, and Adcirca. On December 13, 2023, …

  • 3 Top Pharma Stocks for Investors Betting on a Biotech Boom 26 Feb 2024 16:59 GMT

    FDA approval of its seizure drug and 60 Degrees Pharmaceuticals … These products include treatment for cartilage defects … products are Cymbalta®, Adcirca®, Humulin®, Mounjaro®, and … products through its prescription medicines, vaccines, biological therapies, …

  • Are These 4 Biotech Stocks Worth Buying in 2024? 10 Jan 2024 01:09 GMT

    … strong BioMarin Pharmaceutical Inc. … drug discovery and vaccine development, identify targeted diseases, come up with breakthrough treatments … , and enhance clinical trials. The use of artificial intelligence in the biotechnology … , and Adcirca. In …

  • Verquvo interactions: Alcohol, medications, and other factors 05 Jan 2024 16:29 GMT

    … from the FDA. For details … Adcirca) vardenafil Steps you or your doctor may take: Your doctortreatment with Verquvo, talk with your doctor. Verquvo interactions with vaccinesdoctor or another healthcare professional before taking any medication. The drug

  • 2018 First Generic Drug Approvals 14 Sep 2023 00:55 GMT

    … , long-term opioid treatment and for which alternative treatment options are inadequate … Injection USP, 100 grams Samson Medical Technologies, L.L.C. Maxipime … Tablets USP, 20 mg Mylan Pharmaceuticals Inc. Adcirca (Tadalafil) Tablets, 20 mg …

  • CMP Pharma, Inc Announces that Tadliq®, the First and Only FDA-approved Liquid Suspension of Tadalafil, is Now Available 25 Oct 2022 02:21 GMT

    treatment of pulmonary arterial hypertension and ensures consistent dosing. FDA … in pharmaceutical development and manufacturing to provide medicines to … reaction to TADLIQ, ADCIRCA® or CIALIS® Warnings … -FDA-1088 or www.fda.gov/medwatch. Drug

Satisfied with the content?

Continue to create your account.